ArticleCancer cell international2026
Novel function of GTPBP2 in promoting hepatocellular carcinoma progression through inhibition of BTRC-mediated KRAS degradation.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundDespite recent advancements in targeted therapies for hepatocellular carcinoma (HCC), therapeutic resistance continues to limit their clinical efficacy, highlighting an urgent need to identify novel molecular targets involved in disease progression and drug resistance.
methodsBoth gene set enrichment analysis (GSEA) and experimental gene expression analysis were employed to evaluate the role of GTPBP2 expression in HCC clinicopathogenesis using HCC tissue specimens and cell lines.
resultsIn this study, we reveal for the first time, the critical role of GTP-binding protein 2 (GTPBP2) as a key contributor to HCC progression and resistance to sorafenib treatment. Our findings demonstrate significant overexpression of GTPBP2 in HCC tissues compared to adjacent normal liver tissues, which strongly correlates with advanced tumor stage, increased tumor size, elevated alpha-fetoprotein (AFP) levels, enhanced sorafenib resistance, and poorer patient survival outcomes. Functional studies further confirm that GTPBP2 promotes aggressive tumor behaviors, including enhanced cell migration and invasion. Mechanistically, we uncover a novel function of GTPBP2 in stabilizing the KRAS oncoprotein by competitively binding βTrCP/BTRC, thus inhibiting KRAS ubiquitination and subsequent degradation. Consequently, this stabilization results in elevated activation of crucial downstream signaling pathways, such as p-AKT and p-MEK, which are implicated in tumor growth, metastasis, and drug resistance.
conclusionsCollectively, our study identifies GTPBP2 as a promising novel biomarker and therapeutic target, providing essential insights into HCC pathogenesis and offering new translational opportunities to overcome treatment resistance and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.